Key Takeaways KRYS expects Q4 Vyjuvek revenues of $106-$107M on a preliminary basis, lifting full-year sales to $388-$389M.KRYS benefited from strong U.S. uptake and expanded Vyjuvek approvals across Europe and Japan.KRYS expects key 2026 catalysts, including top-line data from KB801 and KB803 registrational studies.Krystal Biotech, Inc. (KRYS) expects preliminary unaudited net product revenues of $106-$107 million from lead drug Vyjuvek in the fourth quarter of 2025, bringing full-year 2025 revenue forecas ...

PresentationAnd with that, I will pass over to Krish and Suma to kick things off.Good morning, everyone, and welcome I hope you enjoyed the beginning of the conference. My name is Alex Buckley. I'm with the Healthcare Investment Banking Group at JPMorgan. And it's my pleasure to introduce firstly, Krystal Biotech. And joining us is Krish Krishnan, CEO and Chairman; and Suma Krishnan, President of R&D. We'll have some time at the end for Q&A. If you could just raise your hand and a microphone will be passed ...

PresentationBefore we begin, let me just outline a few logistics. During the presentations, the presenters will be on screen. [Operator Instructions]. And with that, I'll now hand over to Paul Hanratty.Good afternoon, ladies and gentlemen. My name is [indiscernible], and I am here of Investor Relations. Thank you all for joining us on this call.Paul HanrattyGroup CEO & Executive Director Thank you very much, and good afternoon, ladies and gentlemen. Thank you very much for joining us on this call. Can I sta ...

Krystal Biotech (NasdaqGS:KRYS) FY Conference January 12, 2026 10:30 AM ET Company ParticipantsDaniel Wilson - CFOKrish Krishnan - CEO and ChairmanSuma Krishnan - Founder & PresidentMatthew Klein - CEOQuentin Blackford - CEOConference Call ParticipantsAllen Gong - AnalystNone - AnalystBrian Cheng - AnalystAlexander Buckley - AnalystAlexander BuckleyGood morning, everyone, and welcome. I hope you enjoy the beginning of the conference. My name is Alex Buckley. I'm with the Healthcare Investment Banking Group ...

This presentation and our discussion contain forward-looking statements that involve substantial risks and uncertainties. Any statements about future expectations, plans, and prospects for Krystal Biotech, Inc. (together with its subsidiaries, the "Company"), including but not limited to, statements about our global VYJUVEK launch; selected preliminary 2025 unaudited results; our 2030 vision and the market potential of the product candidates that could be launched over the next four years; the development a ...

KRYSTAL BIOTECH, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2026 (State or other jurisdiction of incorporation) (Commission File Number) Delaware 001-38210 82-1080209 (IRS Employer Identification Number) 2100 Wharton Street, Suite 701 Pittsburgh, Pennsylvania 15203 ...

新闻内容分析 - 提供的文档内容不包含任何实质性的新闻、事件、财报或行业信息 文档内容仅为一条技术性提示 要求用户启用浏览器Javascript和Cookie 并可能涉及禁用广告拦截器 [1]

Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million Robust clinical pipeline with multibillion dollar opportunities and strong balance sheet for sustained growth PITTSBURGH, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced selected preliminary unaudited 2025 financial results, including fourth quarter and full year 2025 VYJUVEK® net product revenue, and outlined the Company’s strategic vision to drive the next stage of growth of its ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, ...

公司临床项目更新 - Krystal Biotech公司宣布了其囊性纤维化项目KB407的积极中期临床结果 [2] - 结果包括在患者肺部分子水平确认了野生型CFTR蛋白的表达 [2] - 相关新闻稿已发布在公司官网并作为8-K文件提交给美国证券交易委员会 [2] 公司会议参与人员 - 会议由公司企业发展副总裁Stephane Paquette主持 [1][2] - 参与人员包括公司董事长兼首席执行官Krish Krishnan、研发总裁Suma Krishnan、产品开发副总裁Trevor Parry、临床开发总监David Sweet [2] - 外部专家包括佛罗里达大学医学教授、成人囊性纤维化项目副主任兼囊性纤维化治疗开发中心主任Jorge Lascano博士 [2]